Tanzanija - anglų - Tanzania Medicinces & Medical Devices Authority

mega lifesciences (australia) pty limited, australia - telmisartan - tablets - 40

Tanzanija - anglų - Tanzania Medicinces & Medical Devices Authority

mega lifesciences (australia) pty limited, australia - telmisartan - tablets - 40

Tanzanija - anglų - Tanzania Medicinces & Medical Devices Authority

mega lifesciences (australia) pty limited, australia - montelukast - tablets - -

Tanzanija - anglų - Tanzania Medicinces & Medical Devices Authority

mega lifesciences (australia) pty limited, australia - metformin hydrochloride - tablets - 500mg

Tanzanija - anglų - Tanzania Medicinces & Medical Devices Authority

mega lifesciences (australia) pty limited, australia - ferrous fumerate equivalent to iron bp , folic acid bp , cyanocobalamin usp , ascorbic acid usp , zinc sulphate bp - suspension, oral - 100/32.87/0.5/0.005 mg

Tanzanija - anglų - Tanzania Medicinces & Medical Devices Authority

mega lifesciences (australia) pty. limited, australia - metronidazole , miconazole - suppositories - 500 + 100 mg

Tanzanija - anglų - Tanzania Medicinces & Medical Devices Authority

mega lifesciences (australia) pty limited, australia - metronidazole , miconazole - suppositories - 500/100

Tanzanija - anglų - Tanzania Medicinces & Medical Devices Authority

mega lifesciences (australia) pty limited, australia - metronidazole , miconazole , lidocaine - tablet, coated - 750+200+100

Australija - anglų - Department of Health (Therapeutic Goods Administration)

mega lifesciences (australia) pty ltd - cyanocobalamin,ferrous fumarate,folic acid -

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

par pharmaceutical inc. - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 900 mg - omega-3-acid ethyl esters capsules, usp are indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, usp and should continue this diet during treatment with omega-3-acid ethyl esters capsules, usp. laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting  therapy with omega-3-acid ethyl esters. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug ther